GleamWall
中文EN

AMIX Autonomix Medical, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1617867 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-176.0%
ROA-146.1%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio2.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$1.58M$1.51M$1.46M$1.72M$2.37M$1.59M$1.55M$1.04M
SG&A expense$1.59M$1.25M$1.28M$1.62M$5.17M$1.83M$1.70M$1.70M
Operating income-$3.18M-$2.77M-$2.74M-$3.34M-$7.53M-$3.42M-$3.25M-$2.75M
Interest expense——$0$0$0$0$46,000$45,000
Pretax income-$3.13M-$2.73M-$2.67M-$3.26M-$7.45M-$3.34M-$3.19M-$2.71M
Income tax$0$0$0$0$0$0$0$0
Net income-$3.13M-$2.73M-$2.67M-$3.26M-$7.45M-$3.34M-$3.19M-$2.71M
EBITDA-$3.17M-$2.77M-$2.73M-$3.34M-$7.53M-$3.42M-$3.20M-$2.70M
EPS (basic)-2.51-5.02—-0.36-29.02-22.69—-1.46
EPS (diluted)————————
Balance sheet
Cash & equivalents$7.69M$3.46M$7.00M$9.93M$7.48M$8.59M$9.14M$11.82M
Current assets$8.18M$3.96M$7.58M$10.19M$7.89M$8.98M$9.61M$11.93M
PP&E, net$19,000$16,000$19,000$20,000$16,000$19,000$21,000$20,000
Total assets$8.20M$3.98M$7.60M$10.21M$7.93M$9.00M$9.81M$11.95M
Current liabilities$1.25M$818,000$1.71M$1.65M$1.49M$1.97M$1.71M$2.25M
Short-term debt———————$1.13M
Total liabilities$1.25M$818,000$1.71M$1.65M$1.49M$1.97M$1.71M$2.25M
Shareholders' equity$6.94M$3.16M$5.89M$8.56M$6.45M$7.03M$8.10M$9.71M
Shares outstanding1.96M542,312542,31211.41M6.19M4.02M2.50M2.46M
Cash flow statement
Operating cash flow-$2.61M-$3.54M-$2.89M-$2.97M-$3.82M-$2.60M-$2.55M-$2.30M
Capital expenditure——$3,000$7,000$0$0$4,000$5,000
Free cash flow——-$2.90M-$2.98M-$3.82M-$2.60M-$2.56M-$2.31M
Investing cash flow——-$3,000-$7,000$0$0-$4,000-$5,000
Financing cash flow$6.85M$0-$35,000$5.43M$2.71M$2.06M-$174,000$8.97M
Depreciation & amortization$4,000$3,000$3,000$4,000$2,000$3,000$48,000$47,000
Stock-based compensation$53,000$2,000$1,000$2,000$138,000$388,000$405,000$418,000

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.